YL201 Clinical Trials
8 recruitingDrug
Phase 16Phase 24Phase 32
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled4 locationsNCT07407933
Recruiting
Phase 1
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
Amgen200 enrolled36 locationsNCT06898957
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.202 enrolled20 locationsNCT07258979
Recruiting
Phase 1Phase 2
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.260 enrolled1 locationNCT07208773
Recruiting
Phase 1Phase 2
A Study of YL201 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.312 enrolled45 locationsNCT05434234
Recruiting
Phase 1
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.162 enrolled30 locationsNCT06394414
Recruiting
Phase 3
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.438 enrolled1 locationNCT06612151
Recruiting
Phase 3
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.400 enrolled1 locationNCT06629597